Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma

Sequencing studies have deciphered the genetic landscape of primary central nervous system lymphoma (PCNSL) paving novel therapeutic avenues in recent years.1,2

Saved in:

Bibliographic Details
Main Authors:	Kaulen, Leon D. (Author) , Gumbinger, Christoph (Author) , Hinz, Felix (Author) , Keßler, Tobias (Author) , Winkler, Frank (Author) , Bendszus, Martin (Author) , Sahm, Felix (Author) , Wick, Wolfgang (Author)
Format:	Article (Journal)
Language:	English
Published:	13 April 2022
In:	Neuro-oncology advances Year: 2022, Volume: 4, Issue: 1, Pages: 1-4
ISSN:	2632-2498
DOI:	10.1093/noajnl/vdac051
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1093/noajnl/vdac051 Verlag, kostenfrei, Volltext: https://academic.oup.com/noa/article/4/1/vdac051/6568032
Author Notes:	Leon D. Kaulen, Christoph Gumbinger, Felix Hinz, Tobias Kessler, Frank Winkler, Martin Bendszus, Felix Sahm, and Wolfgang Wick

Description
Summary:	Sequencing studies have deciphered the genetic landscape of primary central nervous system lymphoma (PCNSL) paving novel therapeutic avenues in recent years.1,2
Item Description:	Gesehen am 09.06.2022
Physical Description:	Online Resource
ISSN:	2632-2498
DOI:	10.1093/noajnl/vdac051